Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease associated with liver-related complications and death. The efficacy and safety of tirzepatide, an agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, in patients with MASH and moderate or severe fibrosis is unclear. METHODS: We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks. The primary end point was resolution of MASH without worsening of fibrosis at 52 weeks. A key secondary end point was an improvement (decrease) of at least one fibrosis stage without worsening of MASH. RESULTS: Among 190 participants who had undergone randomization, 157 had liver-biopsy results at week 52 that could be evaluated, with missing values imputed under the assumption that they would follow the pattern of results in the placebo group. The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons). The percentage of participants who had an improvement of at least one fibrosis stage without worsening of MASH was 30% in the placebo group, 55% in the 5-mg tirzepatide group (difference vs. placebo, 25 percentage points; 95% CI, 5 to 46), 51% in the 10-mg tirzepatide group (difference, 22 percentage points; 95% CI, 1 to 42), and 51% in the 15-mg tirzepatide group (difference, 21 percentage points; 95% CI, 1 to 42). The most common adverse events in the tirzepatide groups were gastrointestinal events, and most were mild or moderate in severity. CONCLUSIONS: In this phase 2 trial involving participants with MASH and moderate or severe fibrosis, treatment with tirzepatide for 52 weeks was more effective than placebo with respect to resolution of MASH without worsening of fibrosis. Larger and longer trials are needed to further assess the efficacy and safety of tirzepatide for the treatment of MASH. (Funded by Eli Lilly; SYNERGY-NASH ClinicalTrials.gov number, NCT04166773.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The primary outcome for all three studies was resolution of fatty liver disease without worsening of fibrosis, and significant improvements were noted.”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [83]
In the citing paper
“tirzepatide led to an increased proportion of participants reaching an improvement in fibrosis by at least one stage.83”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [83]
In the citing paper
“Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28–30].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [29]
In the citing paper
“Other recent analyses have revealed survodutide, tirzepatide, and retatrutide to each significantly reduce liver fat with no evidence of worsening in markers of liver fibrosis.77, 78, 79”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [79]
In the citing paper
“tirzepatide also increased the proportion of patients achieving at least one-stage fibrosis improvement without MASH worsening (approximately 51–55% vs. 30% with placebo).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [224]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationVilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citation
Cited by
Items 801–900 of 999
Garrido, N. J., Suárez, M., & Mateo, J. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i5.117567
Sun, X., Jiang, H.-L., Ma, Y.-T., Xiong, T.-Q., Leng, X.-Y., Zhao, Y.-F., Shen, X., Zhang, C., & Tang, Y.-J. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08219-6 · Cited by 1
Self-citationZhen, X. M., Macdonald, A., Woodham, B. L., Ryan, B., Hng, T., Nettel‐Aguirre, A., Azar, E., Hanna, M., Yap, J., Paulose, J., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113342
Alnagar, A., Khan, M. U., Ahmad, M. S., Mersal, M., Ayyad, M., Hassan, R., & Noormohamed, M. S. (2026) · World Journal of Transplantation · doi:10.5500/wjt.v16.i2.118702
Hepatic steatosis: A pandemic disease causing serious secondary diseases
Canbay, A., Figge, A., Patsalis, P., Baars, T., Özcürümez, M. K., & Götze, O. (2026) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2026.0074
Duman, T. T., Ucar, Y., Turkoglu, E. S., Tel, B. M. A., Bilgin, S., & Aktaş, G. (2026) · World Journal of Diabetes · doi:10.4239/wjd.119285 · Cited by 2
Nor-ursodeoxycholic acid in hepatobiliary diseases: A narrative review
Malakar, S., Sood, N., Giri, S., & Samanta, A. (2026) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.120122
Hu, J.-H., Chang, M., Huang, T., Liu, N., & Hsieh, Y.-Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1874720
Tirzepatide in type 1 diabetes: beyond mere weight loss
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2685653
Pan, Y., Song, F., Liu, X., (8098), Y. Z., Zhang, J., Song, G., & Ren, L. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04986-0 · Cited by 1
Obesity, Liver Disease, and the Patient Voice: A Clinical Dialogue Podcast
Poddar, M., & Nadglowski, J. F. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03648-7
Wang, X., Yang, Y., Han, S., Liu, Z., Ping, F., Li, W., Xu, L., Zhang, H., & Li, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1850528
Cruz, A. M., Lima, B. C. V., Ferreira, J. E. D. S. M., & Teles, R. B. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04095-7 · Cited by 3
Mechanism-driven therapy for diabetic cardiovascular disease
Sanchis‐Gomar, F., Lavie, C. J., Carbone, S., & Neeland, I. J. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.84
Dasarathy, S., Mitchell, E. P., Wilson, L. A., Neuschwander‐Tetri, B. A., Chalasani, N., Clark, J. M., Diehl, A. M., Hameed, B., Loomba, R. S., Yuan, L., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001797 · Cited by 2
Self-citationPharmacological treatment of obstructive sleep apnea syndrome
Tardov, M. V., Boldin, A. V., Афанасьевич, Ф. А., Kotidis, I. M., Бокова, И. А., Tardova, V. M., & Bokova, O. A. (2026) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202612605248 · Cited by 1
Zarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
Vaitha, R., Lakha, A. S., D’Costa, J., Atife, M., Munro, J., Fateen, W., Barnes, E. J., & Gordon-Weeks, A. N. (2026) · Clinical Surgical Oncology · doi:10.1016/j.cson.2026.100136
Han, S., Shin, J., Kim, J. C., & Na, D. H. (2026) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-026-00815-4
Nutrition Therapy for Metabolic Liver Disease and Diabetes
Guinane, A., & Pezzuto, D. (2026) · American Diabetes Association eBooks · doi:10.2337/9781580408493-ch15
Pharmacologic management of metabolic and alcohol-associated liver disease
Pagadala, M., Jalil, S., Dunn, N., & Singal, A. K. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.29
Incretin-based therapy for MASH: are two better than one?
Sterling, R. K. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.74
Patil, M., Piccinini, F., Johnstone, E. K. M., Casari, I., & Falasca, M. (2026) · Bioscience Reports · doi:10.1042/bsr20250114 · Cited by 1
Salvati, A., Bertellotti, L., Faita, F., Campani, D., Petralli, G., Cappelli, S., Bonino, F., & Brunetto, M. R. (2026) · Livers · doi:10.3390/livers6030054
Lebererkrankungen als Komplikation des Diabetes mellitus
KAHL, S., & Huttasch, M. (2026) · Info Diabetologie · doi:10.1007/s15034-026-5273-x
Bergia, R. E., Brown, A. W., Braun, M. M., & Messina, M. J. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100689 · Cited by 1
Xiao-yu, Z., Wu, Q., Lu, H.-L., Xie, J.-J., Zhang, Y., Xu, Y., Guo, M., & Teng, F. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02163-7 · Cited by 2
Extracellular matrix proteins as risk markers for complications in type 1 diabetes
Rygg, M. O., MØLLER, A. L., Curovic, V. R., Rasmussen, D. G. K., Theilade, S., Tofte, N., Winther, S. A., Genovese, F., Karsdal, M. A., Kümler, T., et al. (2026) · Diabetic Medicine · doi:10.1111/dme.70396
Delivery devices and container closure systems for co-formulated and co-administered biologics
Zhou, M., Duffy, K. H., Mitchener, C., Shi, G. H., & Collins, D. S. (2026) · Antibody Therapeutics · doi:10.1093/abt/tbag034
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
GLP-1 Receptor Agonists beyond Glycemic Control: Physiology and Pharmacological Evidence
Amate, P. (2026) · Open Journal of Pharmacology and Pharmacotherapeutics · doi:10.17352/ojpp.000029
Solís, R. S., Baeza-Zapata, A., & Negrete‐Najar, J. P. (2026) · Cureus · doi:10.7759/cureus.111728
Sawamura, T., Maeno, M., Nishimoto, Y., Ohmori, A., Kometani, M., Karashima, S., & Yoneda, T. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.06.008
Maevskaya, M. V., Okovityi, S. V., Бакулин, И. Г., Bidzhiev, A. S., Glushenkov, D. V., Gurova, O. Y., Gorshkov, A. Y., Амантаевна, Ж. В., Zolnikova, O. Y., Каримов, М. М., et al. (2026) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2026-36-3-7-20
Oliver, J. E., Anombem, O., Zeng, G., Tompkins, R., Youngblood, T., Griffin, S., & Ferrer, C. (2026) · Texas Family Medicine Research Journal · doi:10.65738/001c.164252
Ciancimino, G., Pecorella, F., Viscardi, S. M., Mantia, C. L., Caserta, A., Pennisi, G., & Petta, S. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.19
Fu, H., & Saltiel, A. R. (2026) · Cell Research · doi:10.1038/s41422-026-01271-3
Long-term lessons from MATCH01 macrophage therapy in cirrhosis
Ding, B., Yang, B., & Cao, Z. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.05.016
Mare, R., Ferro, Y., Maurotti, S., Mazza, E., Castagna, A., Pujia, C., Noto, F. R., Galluccio, A., Mirarchi, A., Giampà, G., et al. (2026) · European Journal of Nutrition · doi:10.1007/s00394-026-04049-w
Khalil, I., Sarker, P., Nur, N., Hossain, M. S., Khalid, A. A., Al-Badri, S. G., Akter, M. M., Das, M., & Rahman, M. T. (2026) · Hepatology International · doi:10.1007/s12072-026-11122-3
Galasso, M., Verde, L., Patrone, R., Ragozzino, G., Annunziata, G., Colao, A., Barrea, L., & Muscogiuri, G. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1855886 · Cited by 2
Gorban, V. V., Витальевна, Г. Е., & Kocherga, P. E. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-194
Imaging-based fibrosis assessment and risk stratification in MASLD
Jin, S., Zhou, T., Jin, D., Xie, J., Sheng, G., Li, H., Li, G., Qin, C., & Gao, P. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1880238 · Cited by 1
Joshi, D. M. (2026) · Cureus · doi:10.7759/cureus.112135
Ekstrom, V. S. M. (2026) · npj gut and liver. · doi:10.1038/s44355-026-00070-2
Nascimento, F. B. C., Araújo, P. Q. D., dos Santos, G. S., Vecchi, L. G., Brandão, J. D., & Paiva-Oliveira, E. L. (2026) · Research Society and Development · doi:10.33448/rsd-v15i7.51349
Wu, J., Zheng, W., Qi, Q., He, C., Zhai, C., & Fan, H. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm51234 · Cited by 1
Pendrey, A., Sierra, J. A. R., Lobo, F. A. A., Herrera, E. J. R., Muñoz, Y. M. F., & Sevilla‐Martir, J. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03702-4
Labate, A. M., Cimino, E., Giacomelli, L., Ettori, S., Oladeji, O. A., & Agosti, B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146170 · Cited by 1
Spiazzi, B. F., Zingano, C. P., Colpani, V., & Gerchman, F. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113431 · Cited by 3
Sargis, R. M., Reutrakul, S., Trasande, L., & Nadal, Á. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01635-4
Research Progress of Tirzepatide in Metabolic Diseases
孙, 豪. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1672603
MASH as a network disease: therapeutic modulation of interorgan immunometabolic architecture
Crespo, J., Jiménez-González, C., & Iruzubieta, P. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.54
Zhao, R., Yang, J., Han, M., Tang, S., Hu, H., Guo, J., Ma, M., Sun, J., & Zhou, X. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146438
Metabolic Syndrome: Redefine and Expand Its Reach, Yet Preserve Its Clinical Value
Saad, M. J. A., Santos, A., Geloneze, B., & Velloso, L. A. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.07.008 · Cited by 1
Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations
Newsome, J. S. (2026) · Journal of Pharmacy Technology · doi:10.1177/87551225261466571
Lawitz, E., Poordad, F. F., & Goodman, Z. D. (2026) · Liver International · doi:10.1111/liv.70808
Self-citationReitz, J., Rosoff, D. B., Pacher, P., & Lohoff, F. W. (2026) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2026.100793 · Cited by 1
Chouik, Y., Canivet, C. M., Julla, J., Mouillot, T., Parlati, L., Rouland, A., Smati, S., Tramunt, B., Anty, R., Boursier, J., et al. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.06.013
Self-citationBeyond Fat: Reframing MASLD Through Genetics, Clonal Biology, and Precision Hepatology
Crespo, J., Alonso‐Peña, M., Jiménez-González, C., Cayon, L., & Iruzubieta, P. (2026) · Pharmaceuticals · doi:10.3390/ph19081145
Sun, S., Wang, C., Yuan, M., & Min, H. (2026) · Hepatology International · doi:10.1007/s12072-026-11132-1
Zhu, S., Yang, F., Lu, H., Jiang, J., & He, W. Q. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1843719
Vozza, A., Biagi, F., Chiara, R., Vizzutti, F., & Marra, F. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04456-1 · Cited by 1
Caponio, D., Acucella, G. A., & Acucella, M. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02759-5 · Cited by 1
Guo, S., Liu, B., Li, H., Yu, Y., & Xu, J. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1878927
Risk stratification of MASLD/MASH in type 2 diabetes: a pragmatic endocrinology outpatient pathway
Cai, Y., Zeng, F., & Liu, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1922533 · Cited by 3
Reece, S. W., Choi, H., & Clements, J. N. (2026) · ADCES in Practice · doi:10.1177/2633559x261443514
Adipose Tissue Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease
Cruz, A. J. L., & Yuan, L. (2026) · Cells · doi:10.3390/cells15151377 · Cited by 1
Soloveva, A. E., Park, J. J., Apostolou, E., Böhm, M., Cannata, A. N., Fudim, M., Kittipibul, V., Mueller, S., Potapova, K., Schattenberg, J. M., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag243
Mohamed, Z. I., Shidane, A. A., Abdiasis, A. M., Hussein, M. H., Ibrahim, A. O., Abdi, A. A., Hashi, K. I., Mohamud, M. A., & Mohamed, A. J. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70298
Changement dans la prise en charge de l’obésité : vision du clinicien
Montastier, É. (2026) · Biologie Aujourd hui · doi:10.1051/jbio/2026002
Xiu, H., Li, T., Wen, J., Li, Z. B., Wu, J., Fu, X., Zhang, C., Yang, Z., Yao, X., & Xu, Z. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70416
MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice
Li, S., Toutoungy, M., Patel, J., Bhavsar‐Burke, I., & VanWagner, L. B. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01380-9 · Cited by 2
MASLD: Spatial Mechanisms and New Therapeutics
Stoess, C., Onyuru, J., Hu, Y., Jiang, Y., Xin, Z., Panchal, A., & Hartmann, P. (2026) · Biomolecules · doi:10.3390/biom16081129
Unpacking adiposity: a narrative critical appraisal of diverse obesity definitions
Mancini, M. C., Halpern, B., de Melo, M. E., & Kramer, C. K. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02261-6
Interorgan Crosstalk in MASLD: A Narrative Review
Lonardo, A., & Weiskirchen, R. (2026) · Biomedicines · doi:10.3390/biomedicines14091949 · Cited by 1
Tsai, S. Y., Uwera, G. B., Roehm, B. A., Pandey, A., & VanWagner, L. B. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001209
Management of cirrhosis in diabetes: a pragmatic approach to the patient
Kumar, A., & Basu, R. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag321
Giannoukakis, N. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1901478
Zhong, M.-Y., Yang, S.-Y., Xu, W.-H., Zhang, Y.-K., & Zhao, J. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00544-y
Ahmed, Z., Mustafa, N., Sarkar, T., & Yasmin, H. (2026) · Health Science Reports · doi:10.1002/hsr2.73044
Ren, Y., Hu, D., Li, L., Wang, L., & Meng, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1911290
Mantovani, A., & Lombardi, R. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104958
Xie, Y., Zhang, X., & Chen, B. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1913929
Cree, M. G., Dunsmoor-Su, R. F., Khoudary, S. R. E., Hurtado, M. D., Kapoor, E., Neal-Perry, G. S., & Santoro, N. F. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100321
Canecki-Varžić, S., Bilić-Čurčić, I., Bakula, M., Bulum, T., Naglić, M. Č., Delić-Brkljačić, D., Wensveen, T. T., Vitković, D. F., Jurišić‐Eržen, D., Klobučar, S., et al. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1834323 · Cited by 1
Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis
Chen, Q.-X., Xiao-yu, Z., Wu, Q., Xie, J.-J., Xu, Y., Teng, F., & Guo, M. (2026) · Endocrine · doi:10.1007/s12020-026-04757-7
Synchronizing obesity management with survodutide
Lonardo, A., & Weiskirchen, R. (2026) · Exploration of Drug Science · doi:10.37349/eds.2026.1008175
Kehar, M., Ramji, A. S., Swain, M., Singer, A. G., IVERS, N., Schaufert, W., Betel, M., Dasgupta, K., Sebastiani, G., & Patel, K. (2026) · Canadian Liver Journal · doi:10.3138/canlivj-2026-9-3-guidelines
Du, Y., Qi, L., Shi, Y., Huang, X., Shi, X., Liu, M., Fang, Y., & Hu, X. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1912000
Incretins beyond weight and hyperglycemia management: a consensus statement by AASD
Shaltout, I., Hegazy, M., Meligi, A. A. H. E., Abdelghaffar, S., Wifi, M.-N. A., Saleh, A. A., Hammad, H., Abouzeid, A. A. E. K., Fahmy, E. M., Maghraby, G. G., et al. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00689-w
Ayoub, M., Tsutsumi, T., & Rinella, M. E. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70921 · Cited by 2
He, W., Yi-di, S., Wang, X., He, S.-Y., Tao, X., Yuan, S.-X., Zhou, L., & Long, E.-W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1889594
Banerjee, M., Roy, A., Sharma, V. M., & Das, A. (2026) · Obesity · doi:10.1002/oby.70277
Shen, Y., Jiang, D., Zhu, A., Fan, Y., Fu, T. T., Yu, J., Miao, Y., Han, H., Zhu, Y., Xu, H., et al. (2026) · European Radiology · doi:10.1007/s00330-026-12807-x
Rethinking Global Obesity Guidelines: Integrating Evidence, Equity and Precision (2014–2026)
Rosero, R., Tamayo, M., Henao, D. C., Polanco, J. P., David, C., Alba, J. C., Valeria, G., Camilo, C., Eder, H., Ricardo, C., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70209
Plant-Derived Exosome-like Nanovesicles for Metabolic Dysfunction-Associated Steatotic Liver Disease
Kuang, T., Wang, L., Shi, Y., Cheng, J., & Pan, S. (2026) · Veterinary Sciences · doi:10.3390/vetsci13090851 · Cited by 1
Zhao, Z., & Hu, X. (2026) · Biomedicines · doi:10.3390/biomedicines14091884
Metadata
- Authors
- Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., Brouwers, B., Robins, D. A., Nikooie, A., Bunck, M. C., Haupt, A., & Sanyal, A. J.
- Affiliations
- University of California San Diego (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-25
- Volume
- 391
- Issue
- 4
- Pages
- 299-310
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399461049
- Cited by
- 1,005
- References
- 37
- Citations by year
- 2026: 458 · 2025: 433 · 2024: 114
- FWCI
- 306.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, nonalcoholic steatohepatitis, liver fibrosis, GIP/GLP-1 receptor agonist, fibrosis regression, dose-response relationship, liver biopsy, non-alcoholic fatty liver disease, obesity, type 2 diabetes, weight loss, drug safety, adverse events, liver complications, hepatocellular carcinoma, liver cirrhosis
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Fatty Liver, Female, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.